白蛋白结合型紫衫醇与紫杉醇联合洛铂治疗中晚期宫颈癌患者的效果比较  

Comparison of effects of Albumin-bound paclitaxel and Paclitaxel combined with Lobaplatin in treatment of patients with advanced cervical cancer

作　　者：徐倩文 张爱梅[1] 文宁[1] XU Qianwen;ZHANG Aimei;WEN Ning(Department of Gynecology of Suiping County People’s Hospital,Zhumadian 463100 Henan,China)

机构地区：[1]遂平县人民医院妇科,河南驻马店463100

出　　处：《中国民康医学》2024年第20期145-148,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:比较白蛋白结合型紫衫醇与紫杉醇联合洛铂治疗中晚期宫颈癌患者的效果。方法:选取2021年2月至2023年2月该院收治的78例中晚期宫颈癌患者进行前瞻性研究,按照随机数字表法将其分为研究组与对照组各39例,对照组采用紫杉醇联合洛铂治疗,研究组采用白蛋白结合型紫衫醇联合洛铂治疗,比较两组临床疗效,治疗前后血管内皮生长因子(VEGF)水平、肿瘤标志物[细胞质胸苷激酶(TK1)、鳞状细胞癌抗原(SCC)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)]水平、生命质量[卡氏功能状态(KPS)]评分,以及不良反应发生率。结果:研究组客观缓解率为94.87%(37/39),高于对照组的79.49%(31/39),差异有统计学意义(P<0.05);治疗后,两组VEGF水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组TK1、SCC、CYFRA21-1水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组KPS评分均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05);研究组不良反应发生率为10.26%(4/39),低于对照组的28.21%(11/39),差异有统计学意义(P<0.05)。结论:白蛋白结合紫衫醇联合洛铂治疗中晚期宫颈癌患者可提高客观缓解率和生命质量评分,以及降低血清肿瘤标志物水平、VEGF水平和不良反应发生率的效果优于紫杉醇联合洛铂治疗。Objective:To compare effects of Albumin-bound paclitaxel and Paclitaxel combined with Lobaplatin in treatment of patients with advanced cervical cancer.Methods:A prospective study was conducted on 78 patients with advanced cervical cancer admitted to this hospital from February 2021 to February 2023.According to the random number table method,they were divided into study group and control group,39 cases in each group.The control group was treated with Paclitaxel combined with Lobaplatin,while the study group was treated with Albumin-bound paclitaxel combined with Lobaplatin.The clinical efficacy,the vascular endothelial growth factor(VEGF)levels,the tumor markers[cytoplasmic thymidine kinase 1(TK1),squamous cell carcinoma antigen(SCC),cyto-keratin 19 fragment antigen 21-1(CYFRA21-1)]levels,the quality of life[Karnofsky performance status(KPS)]score before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The objective remission rate of the study group was 94.87%(37/39),which was higher than 79.49%(31/39)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the VEGF levels of the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of TK1,SCC and CYFRA21-1 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the KPS scores of the two groups were higher than those before the treatment,that in the study group was higher than that in the control group,and the differences were statistically significant(P<0.05).Further,the incidence of adverse reactions in the study group was 10.26%(4/39),which was lower than 28.21%(11/39)in the control group,and the differences were statistically significant(P<0.05).Conclusion

关 键 词：白蛋白紫衫醇 洛铂 宫颈癌 肿瘤标志物 血管内皮生长因子 生命质量 不良反应 

分 类 号：R737.33[医药卫生—肿瘤]